Great works new BOD.
All the best new BOD and shares holders
I like the forecast for FY2024
FY24 Outlook The Company is committed to delivering growth for shareholders in FY24 including:
• Net sales revenue $80m, representing a 35% increase on the previous year
• Gross profit margin of 40%
• Continued FDA progress
• Renewed focus on infant & adult goat nutrition
• Working capital improvements
• Improved transparency and governance
• Cash flow positive in FY25.
BUB Price at posting:
21.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)